BriaCell CEO Discusses Positive Clinical Results of its Breast Cancer Immunotherapy Treatment in an Audio Interview with SmallCapVoice.com

Rhea-AI Summary

BriaCell Therapeutics Corp. (BCTX, BCTXW) announced promising initial efficacy results from its phase I/IIaa clinical trial of Bria-IMT™ combined with Incyte’s retifanlimab for advanced breast cancer. Presenting at the SITC annual meeting, they reported a 70% disease control rate and tumor shrinkage in 70% of 12 patients, all of whom had previously failed multiple therapies. The company is in talks with the FDA to progress to pivotal studies, aiming for broader patient access to this innovative treatment.

Positive

• 70% of patients showed disease control and tumor shrinkage.
• Positive initial results from phase I/IIaa clinical trial.
• Ongoing discussions with the FDA for pivotal studies.

Negative

• None.

AUSTIN, Texas, Nov. 15, 2022 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new audio interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT), to discuss the positive initial efficacy data of the Company’s phase I/IIaa clinical study of Bria-IMT™ in combination with Incyte’s retifanlimab in advanced breast cancer.

In a poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 37^th annual meeting earlier this week, BriaCell reported disease control, tumor shrinkage and potential survival benefit among 70% of the 12 patients enrolled in its 2021-2022 group of advanced breast cancer patients. Speaking with SCV’s Stuart Smith, Dr. Williams defines the gravity of advanced breast cancer and the value of this positive data for patients who have failed other therapies.

“We're treating patients with very advanced breast cancer,” Dr. Williams says. “These are patients who have failed at least two prior therapies, but most of them have failed on the average of six to seven prior attempts of therapy for their metastatic breast cancer. These are very difficult-to-treat patients. Their life expectancy is very short; many of them would otherwise be going on hospice.”

BriaCell is now in discussions with the FDA to advance to its pivotal study and move forward with the registration study along the path to FDA approval. “That, of course, is our ultimate goal,” says Dr. Williams. “We want to make this promising therapy available to as many patients as possible.”

The full interview can be heard at: https://www.smallcapvoice.com/november-interview-briacell-therapeutics-corp-bctx-2/.

About BriaCell Therapeutics Corp.

BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://BriaCell.com/ .

About SmallCapVoice.com

SmallCapVoice.com, Inc. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies, small cap and micro-cap stocks build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, podcasts, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks in which they are interested. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTCMarkets. To learn more about SmallCapVoice.com and its services, please visit https://www.smallcapvoice.com/small-cap-stock-otc-investor-relations-financial-public-relations/.

Socialize with SmallCapVoice and their clients at

Facebook: https://www.facebook.com/SmallCapVoice/  
Twitter: https://twitter.com/smallcapvoice   
Instagram: https://www.instagram.com/smallcapvoice/

Safe Harbor

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management’s Discussion and Analysis, under “Risks and Uncertainties” in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under our profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:

Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
Info@BriaCell.com

Media Relations:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
JulesA@CoreIR.com

Investor Relations Contact:
CORE IR
Investors@BriaCell.com

SmallCapVoice.com
Stuart T. Smith
512-267-2430
Info@SmallCapVoice.com

Source: SmallCapVoice.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b7066958-7a74-4d01-b0a1-8f45e388093d 

FAQ

What were the initial results of BriaCell's clinical trial for advanced breast cancer?

BriaCell reported a 70% disease control rate with tumor shrinkage among 70% of the 12 patients enrolled in their phase I/IIaa clinical trial.

What is the next step for BriaCell following the positive clinical trial results?

BriaCell is in discussions with the FDA to advance to a pivotal study and registration study for FDA approval.

How many patients were involved in BriaCell's recent clinical trial presentation?

There were 12 patients involved in the recent clinical trial presentation.

What is the significance of the trial results for advanced breast cancer patients?

The trial results are significant as they provide hope for patients who have failed multiple prior therapies, offering a potential new treatment option.